open access

Vol 20, No 3 (2016)
ORIGINAL PAPERS
Published online: 2016-09-29
Get Citation

Study of the role of L-arginine in the diagnosis of pregnancy-induced hypertension

Agnieszka Grafka, Maciej Łopucki, Katarzyna Karwasik-Kajszczarek, Marzena Stasiak-Kosarzycka, Andrzej Miturski, Grzegorz Dzida
DOI: 10.5603/AH.2016.0017
·
Arterial Hypertension 2016;20(3):113-118.

open access

Vol 20, No 3 (2016)
ORIGINAL PAPERS
Published online: 2016-09-29

Abstract

Background Pregnancy-induced hypertension (PIH) is a significant health issue in pregnancy, complicating 7–10% of pregnancies. L-arginine is an important mediator of vasodilation with a potential preventative role in pregnancy-related hypertensive diseases.

Aim of the study The aim of the present study was to assess the differences in plasma L-arginine concentrations in physiological pregnancies and pregnancies complicated with hypertension in the third trimester.

Material and methods Plasma concentration of L-arginine was determined by ion-exchange chromatography in 210 pregnant women (25–41 weeks of gestation). Plasma L-arginine concentration was expressed in μmol/cm3.

Results The mean L-arginine concentration was significantly higher in physiological pregnancy (0.102) than in the PIH group (0.034). The analysis of plasma L-arginine concentration in the subgroups of third trimester showed that L-arginine concentration in the PIH group decreased with increasing stage of pregnancy (25–34 hbd — 0.051; 35–38 hbd — 0.03; 39–41 hbd — 0.02). L-arginine concentration in physiological pregnancies was the same in all subgroups (0.1).

Conclusions L-arginine may have a role in the prevention and treatment of pregnancy-induced hypertension. Further well-designed and adequately powered research is warranted.

Abstract

Background Pregnancy-induced hypertension (PIH) is a significant health issue in pregnancy, complicating 7–10% of pregnancies. L-arginine is an important mediator of vasodilation with a potential preventative role in pregnancy-related hypertensive diseases.

Aim of the study The aim of the present study was to assess the differences in plasma L-arginine concentrations in physiological pregnancies and pregnancies complicated with hypertension in the third trimester.

Material and methods Plasma concentration of L-arginine was determined by ion-exchange chromatography in 210 pregnant women (25–41 weeks of gestation). Plasma L-arginine concentration was expressed in μmol/cm3.

Results The mean L-arginine concentration was significantly higher in physiological pregnancy (0.102) than in the PIH group (0.034). The analysis of plasma L-arginine concentration in the subgroups of third trimester showed that L-arginine concentration in the PIH group decreased with increasing stage of pregnancy (25–34 hbd — 0.051; 35–38 hbd — 0.03; 39–41 hbd — 0.02). L-arginine concentration in physiological pregnancies was the same in all subgroups (0.1).

Conclusions L-arginine may have a role in the prevention and treatment of pregnancy-induced hypertension. Further well-designed and adequately powered research is warranted.

Full Text:

View HTML
Get Citation

Keywords

L-arginine, pregnant women, hypertension, blood plasma

About this article
Title

Study of the role of L-arginine in the diagnosis of pregnancy-induced hypertension

Journal

Arterial Hypertension

Issue

Vol 20, No 3 (2016)

Pages

113-118

Published online

2016-09-29

DOI

10.5603/AH.2016.0017

Bibliographic record

Arterial Hypertension 2016;20(3):113-118.

Keywords

L-arginine
pregnant women
hypertension
blood plasma

Authors

Agnieszka Grafka
Maciej Łopucki
Katarzyna Karwasik-Kajszczarek
Marzena Stasiak-Kosarzycka
Andrzej Miturski
Grzegorz Dzida

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl